Drilling Down Into Monsanto Company (MON)

Monsanto Company (MON) is an interesting player in the Basic Materials space, with a focus on Agricultural Chemicals. The stock has been active on the tape, currently trading at $124.89, up from yesterday’s close by 0.16%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Monsanto Company (MON) currently trades with a market capitalization of $55.28 Billion. That value represents a market adjusting for revenues that have been falling by -1.08 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of $1.96 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $2.14 on a per share basis this quarter. Perhaps, that suggests something about why 0.49% of the outstanding share supply is held by institutional investors.



Technical Analysis

No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Monsanto Company recorded a 52-week high of $126.80. It is now trading 1.91% off that level. The stock is trading $122.26 its 50-day moving average by -2.63%. The stock carved out a 52-week low down at $114.19.

In recent action, Monsanto Company (MON) has made a move of -0.34% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 12.84, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 1.83% with $439.92 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of MON.

SHARE
Previous articleCerner Corporation (CERN): From Top to Bottom
Next articleThe Case for and Against Immunomedics, Inc. (IMMU)